CG
OSIR

Caprock Group’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Caprock Group’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-35,000
Closed -$473K – 413
2018
Q4 		$473K Buy
35,000
+25,000
+250% +$279K 0.11% 162
2018
Q3 		$111K Buy
+10,000
New +$100K 0.02% 393

Other funds holding OSIR

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Cloverdale Capital Management Dallas, Texas $135M AUM 13.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Caprock Group's OSIR Position: Q1 2019 in Review

Caprock Group sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q1 2019, closing a stake of 35,000 shares — an estimated $473K sold.

Caprock Group first reported a position in OSIR in Q3 2018 and held it in 2 quarters. The position peaked at $473K in Q4 2018. 57 funds tracked by Wall St. Rank hold OSIR as of Q1 2019.

  • Caprock Group reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Caprock Group sold 35,000 Osiris Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $473K.
  • Caprock Group first reported a position in Osiris Therapeutics, Inc. Common Stock in Q3 2018 and held it in 2 quarters.
  • Caprock Group's Osiris Therapeutics, Inc. Common Stock position peaked at $473K in Q4 2018.
  • 57 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Caprock Group's 13F filing for Q1 2019, filed 12 Apr 2019.